| |miglustat - Compound Summary
Also known as: Zavesca, N-Butylmoranoline, NB-DNJ, N-Butyldeoxynojirimycin, n-Butyl deoxynojirimycin, BuDNJ, Butyldeoxynojirimycin
NO4 Molecular Weight:
Miglustat is a drug used to treat Gaucher disease.
It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.
It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase.
It is marketed under the trade name Zavesca.
Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea. From: DrugBank
| |Show subcontent titlesTable of Contents
| || |
Use and Manufacturing
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties